Intervention: Mifamurtide
Trial phase: Phase 2
ATC code: L03AX15
SMILES: CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](C=O)NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+]
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Patients receive Mifamurtide only.

Treatment Weeks 1-6 (post 1st biopsy/resection):

Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.

Treatment Weeks 7-12 (post 2nd biopsy/resection):

Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.

Treatment Weeks 13-36:

Mifamurtide 2mg/m2, IV infusion, once/week.

Mifamurtide
Eligibility criteria:
Inclusion Criteria:

Relapsed osteosarcoma (first, second, third or any relapse, patient has recovered from chemotherapy and any other investigational drug/agent treatment, radiotherapy or surgical procedure).
Histological confirmed diagnosis of osteosarcoma at original presentation.
Tumour at biopsy accessible or resectable site.
Progressive disease documented by imaging within 3 months of entry into the trial.
At least one measurable lesion on CT scan (RECIST) performed in past 21 days prior to trial entry.
Male or female, age ≥ 16 years to 65 (or ≥18 based on institutional practice for Teenage and Young Adult Cancer patients).
Life expectancy of at least 3 months.
WHO performance score of 0 - 2.
The patient is willing and able to comply with the protocol and scheduled follow-up visits and examinations.
Written (signed and dated) informed consent.
Cardiac shortening fraction ≥ 28% or ejection fraction ≥ 45%
Renal function is adequate for ifosfamide treatment (GFR as per table below, other renal function screening tests as per local practice)
Haematological and biochemical indices within the ranges shown below:

Lab Test Value required

Haemoglobin (Hb) ≥ 9 g/dL (Previous transfusion is allowed)
Absolute neutrophil count (ANC) >=1.0 x 10*9/L without growth factor support
Platelet count > 80.x 10*9/L (Previous transfusion is allowed)
Total bilirubin <1.5 times the upper limit of normal (ULN) for age (except for Gilbert's syndrome patients)
Serum alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) <2.5 × ULN for age, <2.5 × ULN for age
Serum creatinine Normal range for age
Glomerular filtration rate (GFR) (calculated as 51Cr-EDTA/99mTc-DTPA clearance) >40ml/min if deemed resectable (for Arm A), >60ml/min if not deemed resectable (for Arm B or C)

Exclusion Criteria:

Pregnant or breast-feeding woman. Men or women of childbearing potential unless effective methods of contraception are used during study treatment and for at least 7 days after the last mifamurtide dose (see section 5.1 Informed consent - Contraceptive/ Pregnancy counselling).
Previous treatment with mifamurtide or a mifamurtide-like drug* in a clinical trial setting for the treatment of metastatic and/or recurrent osteosarcoma in the six months prior to registration.
Contraindications to lung biopsies.
Hypersensitivity to ifosfamide or any component of the formulation.
Previously diagnosed brain metastases.
Significant active cardiac disease including: uncontrolled high blood pressure (no greater than 2 standard deviations above the mean for age for systolic blood pressure (SBP) and diastolic blood pressure (DBP), unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, or serious cardiac arrhythmias and with a history of pericarditis and myocarditis
Treatment with any other investigational agent, or participation in another interventional clinical trial within 21 days prior to enrolment.
Major surgery within 21 days prior to first study biopsy
Currently taking high-dose non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroid treatment
Concurrent use of ciclosporin or other calcineurin inhibitors.
Any psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.
Any other active malignancy, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and non-melanoma skin lesions.

Patients who are known to be serologically positive for Hepatitis B, Hepatitis C or HIV.

mifamurtide-like drugs include GCSF, GMCSF, interferon and other macrophage activating molecules.